Study reveals anti-dementia drugs may delay care home admission

Research has shown that prescribing anti-dementia drugs to patients could delay entry into a care homes by up to a year. The study, published in The Psychiatrist journal last month claimed that patients who took cholinesterase inhibitors, such as donepezil, galantamine, rivastigmine and memantine – among the drugs which caused much controversy just a couple of years ago – could remain in their own homes for up to a year longer than patients who did not take the drugs.

You must be a CM Subscriber to view this content.

Subscribe Now »